10068 – Short-Chain Fatty Acids for the Treatment of Coagulopathy and SARS-CoV-2 Infection

  • Method for treating SARS-CoV-2 infection using a short-chain fatty acid (SCFA) or a fiber-fermenting gut commensal bacteria

Abstract
Background & Unmet Need

  • COVID-19, caused by the SARS-CoV-2 virus, has created unprecedented global health and economic crises
  • The evolution of new SARS-CoV-2 variants may lead to new outbreaks, underscoring the need for additional long-term health solutions that complement vaccination
  • Metabolic diseases are known comorbidities that increase risk of severe SARS-CoV-2 infection, and therefore these patients may benefit from additional therapies to reduce infection rates or disease severity
  • The gut microbiome plays a central role in the regulation of metabolism, but the impact of the gut microbiome on susceptibility to SARS-CoV-2 infection and disease severity remain poorly understood
  • Unmet Need: Therapies that improve the management SARS-CoV-2 infection

Technology Overview

  • The Technology: Method for treating SARS-CoV-2 infection using a short-chain fatty acid (SCFA) or a fiber-fermenting gut commensal bacteria
  • The Discovery: SCFAs, derived from fiber-fermenting gut bacteria, downregulate ACE2 and reduce infection in a mouse model of SARS-CoV-2
  • The SCFAs also dampen the coagulation response, which may help to reduce disease severity in COVID-19 and other viral infections (e.g., SARS, MERS, H1N1 influenza)
  • PoC Data: Hamsters given a 30% pectin diet exhibited reduced luciferase activity in the lung and colon following infection with a SARS-CoV-2 pseudovirus
  • Treatment with SCFAs also ameliorates COVID-19-associated coagulopathy through upregulation of Sh2b3, an adaptor protein that regulates a diverse array of signal transduction pathways

Technology Applications

  • Prebiotic and probiotic formulations for treatment and prevention of SARS-CoV-2 infection
  • Treatment of coagulopathy associated with SARS-CoV-2 infection

Technology Advantages

  • Rigorous data package in an animal model of SARS-CoV-2 infection
  • Many SCFAs, such as pectin, are generally recognized as safe (GRAS) by the FDA, and are already available commercially as dietary supplements

Publications

  • Brown et al. “Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection.” Gut Microbes. 2022.

Patents

  • Provisional Filed

Contact Information

Name: Brian J. Kelly

Email: bjk44@cornell.edu

Phone: 646-962-7045